When persistent nasal congestion, watery eyes, and frequent sneezing disrupt daily life, many turn to medical advice for relief. A recent inquiry from an individual experiencing allergic rhinitis symptoms—including nasal blockage, eye irritation, postnasal drip, and thick yellow discharge—highlighted a common point of confusion: understanding prescribed medications. The user shared they had been given four specific drugs after a hospital visit: ベポテン정10ミリグラム (Bepotastine Besilate 10mg), シトゥス정50mg (Cetirizine Hydrochloride 50mg), ピディ정2ミリ (likely a typo or shorthand for a second-generation antihistamine or nasal spray, though unverified), and a fourth unspecified item. This reflects a widespread scenario where patients seek clarity on treatment regimens for allergic conditions, especially when symptoms interfere with sleep, concentration, or quality of life.
Allergic rhinitis, clinically defined as IgE-mediated inflammation of the nasal mucosa triggered by allergens such as pollen, dust mites, or animal dander, affects up to 30% of adults globally, according to multiple peer-reviewed studies. Symptoms typically include recurrent sneezing, clear or mucoid nasal discharge, nasal itching, and ocular irritation—often worsening during specific seasons or upon exposure to indoor allergens. Even as the user mentioned “yellow nasal discharge,” which may suggest secondary infection or sinus involvement, pure allergic rhinitis usually produces clear secretions. colored discharge warrants evaluation for bacterial sinusitis or other complications, as noted in clinical guidelines from major respiratory associations.
To address the core of the inquiry—interpreting the prescribed medications—each drug must be evaluated based on verified pharmacological data. ベポテン정10ミリグラム refers to Bepotastine Besilate, a second-generation antihistamine available in South Korea and Japan under brand names like Talion. It selectively blocks histamine H1 receptors, reducing sneezing, itching, and rhinorrhea with minimal sedation. Clinical trials demonstrate its efficacy in both seasonal and perennial allergic rhinitis, with a favorable safety profile suitable for daily use. Similarly, シトゥス정50mg corresponds to Cetirizine Hydrochloride 50mg—a dose notably higher than the standard 5–10mg range. While cetirizine is a widely used, non-sedating antihistamine effective for allergic skin and nasal symptoms, 50mg exceeds typical therapeutic limits and may increase risks of drowsiness or anticholinergic effects; such dosing should only occur under strict medical supervision, as no major guideline supports routine use of cetirizine at this level for allergic rhinitis.
The third entry, ピディ정2ミリ, remains ambiguous without further context. It could potentially refer to a nasal corticosteroid spray (e.g., fluticasone propionate at 50mcg per actuation, though “2ミリ” does not align with standard units), an ophthalmic drop for ocular itching, or even a mistranslation of a drug like montelukast (used in allergic asthma and rhinitis). However, without verified product information or clinical documentation, its identity cannot be confirmed. Patients should never assume medication identity based on phonetic similarity or incomplete labels—especially when dealing with drugs that have narrow therapeutic indices or require precise dosing.
Medical professionals emphasize that allergic rhinitis management follows a stepwise approach. First-line intranasal corticosteroids (e.g., mometasone, fluticasone) are recommended for moderate-to-severe symptoms due to their potent anti-inflammatory action on nasal mucosa. Antihistamines like cetirizine or levocetirizine serve as alternatives or adjuncts, particularly for intermittent symptoms or ocular involvement. Leukotriene receptor antagonists (e.g., montelukast) may be added in cases with comorbid asthma. Allergen immunotherapy remains the only disease-modifying option for long-term tolerance in suitable candidates. Crucially, intranasal antihistamines or corticosteroids act locally, minimizing systemic side effects compared to oral agents.
Self-diagnosis or medication sharing based on anecdotal reports poses significant risks. The user’s mention of “thick yellow nasal discharge” raises concern for possible bacterial sinusitis, which requires different treatment—potentially including antibiotics if symptoms persist beyond 10 days or worsen after initial improvement. Similarly, confusing allergic rhinitis with viral upper respiratory infections or non-allergic rhinitis (triggered by weather, strong odors, or hormonal changes) can lead to ineffective therapy. Accurate diagnosis relies on clinical history, physical examination, and, when needed, allergy testing via skin prick or specific IgE blood assays.
For individuals navigating similar symptoms, verified medical sources stress the importance of consulting a licensed otolaryngologist or allergist before initiating or altering treatment. Reliable resources include the American Academy of Allergy, Asthma & Immunology (AAAAI), the European Academy of Allergy and Clinical Immunology (EAACI), and national respiratory societies, all of which provide evidence-based guidelines on rhinitis management. Patients should maintain a symptom diary noting triggers, timing, and severity to aid clinical assessment, and always verify medication names and dosages with a pharmacist or prescribing physician—especially when encountering unfamiliar drug names or non-standard dosing.
As of the latest clinical updates in early 2026, no major changes have been issued to first-line allergic rhinitis treatment protocols by the Global Initiative for Asthma (GINA) or the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative. However, ongoing research continues to refine understanding of biologic therapies for severe, refractory cases, particularly those targeting IgE or thymic stromal lymphopoietin (TSLP). These remain investigational or reserved for specialized care settings.
Understanding your treatment plan is a vital step toward managing allergic rhinitis effectively. If you’ve been prescribed medications for nasal allergies, accept time to review each one with your healthcare provider—ask about purpose, expected benefits, potential side effects, and correct usage. Never adjust doses based on online forums or unverified sources.
Have experience with allergic rhinitis treatments or questions about prescription medications? Share your thoughts in the comments below—we’d love to hear from you. If this article helped clarify your concerns, consider sharing it with others who might benefit from reliable, medically grounded information.